Neurogene
Neurogene secures EMA orphan designation for gene therapy in rare, inherited aspartylglucosaminuria
December 3, 2020Sales and Marketing EMA, Neurogene, aspartylglucosaminuria
The European Medicines Agency (EMA) has bestowed Orphan Drug Designation (ODD) to Neurogene’s adeno-associated virus vector (AAV) gene therapy in …
Latest content
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
